These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1139 related items for PubMed ID: 26998845

  • 1. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
    Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, Costantini B, Margariti PA, Gueli Alletti S, Cosentino F, Tortorella L, Scambia G.
    Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
    [Abstract] [Full Text] [Related]

  • 2. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
    Markauskas A, Mogensen O, dePont Christensen R, Jensen PT.
    Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
    [Abstract] [Full Text] [Related]

  • 3. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B, Noventa M, Cvjeticanin B, Barbic M, Meglic L, Herzog M, Bordi G, Vitagliano A, Saccardi C, Skof E.
    Radiol Oncol; 2018 Sep 11; 52(3):307-319. PubMed ID: 30210049
    [Abstract] [Full Text] [Related]

  • 4. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.
    Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, Reed NS, Nordal RR, Coens C, Vergote I, European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group.
    Gynecol Oncol; 2013 Nov 11; 131(2):437-44. PubMed ID: 23994107
    [Abstract] [Full Text] [Related]

  • 5. Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study.
    Gueli Alletti S, Petrillo M, Vizzielli G, Bottoni C, Nardelli F, Costantini B, Quagliozzi L, Gallotta V, Scambia G, Fagotti A.
    Gynecol Oncol; 2016 Dec 11; 143(3):516-520. PubMed ID: 27769526
    [Abstract] [Full Text] [Related]

  • 6. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
    Onda T, Satoh T, Saito T, Kasamatsu T, Nakanishi T, Nakamura K, Wakabayashi M, Takehara K, Saito M, Ushijima K, Kobayashi H, Kawana K, Yokota H, Takano M, Takeshima N, Watanabe Y, Yaegashi N, Konishi I, Kamura T, Yoshikawa H, Japan Clinical Oncology Group.
    Eur J Cancer; 2016 Sep 11; 64():22-31. PubMed ID: 27323348
    [Abstract] [Full Text] [Related]

  • 7. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL, Bryant A, Kehoe S, Morrison J.
    Cochrane Database Syst Rev; 2021 Jul 30; 7(7):CD005343. PubMed ID: 34328210
    [Abstract] [Full Text] [Related]

  • 8. Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850).
    Marchetti C, Giannarelli D, Vizzielli G, Ferrandina G, Tortorella L, Fanfani F, Costantini B, Pasciuto T, Scambia G, Fagotti A.
    BJOG; 2023 Dec 30; 130(13):1579-1588. PubMed ID: 37334772
    [Abstract] [Full Text] [Related]

  • 9. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.
    Rowland MR, Lesnock JL, Farris C, Kelley JL, Krivak TC.
    Am J Obstet Gynecol; 2015 Jun 30; 212(6):763.e1-8. PubMed ID: 25644442
    [Abstract] [Full Text] [Related]

  • 10. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL.
    Gynecol Oncol; 2017 Feb 30; 144(2):266-273. PubMed ID: 27916269
    [Abstract] [Full Text] [Related]

  • 11. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V, Moruzzi MC, Bizzarri N, Vargiu V, D'Indinosante M, Garganese G, Pasciuto T, Loverro M, Scambia G, Fagotti A.
    Gynecol Oncol; 2020 Apr 30; 157(1):209-213. PubMed ID: 31952843
    [Abstract] [Full Text] [Related]

  • 12. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
    Jiang R, Zhu J, Kim JW, Liu J, Kato K, Kim HS, Zhang Y, Zhang P, Zhu T, Aoki D, Yu A, Chen X, Wang X, Zhu D, Zhang W, Jia H, Shi T, Gao W, Yin S, Feng Y, Xiang L, Okamoto A, Zang R.
    J Gynecol Oncol; 2020 Sep 30; 31(5):e86. PubMed ID: 32808504
    [Abstract] [Full Text] [Related]

  • 13. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH.
    Zhonghua Fu Chan Ke Za Zhi; 2012 May 30; 47(5):355-60. PubMed ID: 22883524
    [Abstract] [Full Text] [Related]

  • 14. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
    da Costa Miranda V, de Souza Fêde ÂB, Dos Anjos CH, da Silva JR, Sanchez FB, da Silva Bessa LR, de Paula Carvalho J, Filho EA, de Freitas D, Del Pilar Estevez Diz M.
    Gynecol Oncol; 2014 Feb 30; 132(2):287-91. PubMed ID: 24333355
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience.
    Fagotti A, Vizzielli G, Fanfani F, Costantini B, Ferrandina G, Gallotta V, Gueli Alletti S, Tortorella L, Scambia G.
    Gynecol Oncol; 2013 Nov 30; 131(2):341-6. PubMed ID: 23938372
    [Abstract] [Full Text] [Related]

  • 18. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
    Maheshwari A, Kumar N, Gupta S, Rekhi B, Shylasree TS, Dusane R, Bajpai J, Ghosh J, Gulia S, Deodhar K, Menon S, Popat P, Sable N, Thakur M, Kerkar R.
    Indian J Cancer; 2018 Nov 30; 55(1):50-54. PubMed ID: 30147093
    [Abstract] [Full Text] [Related]

  • 19. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C, Yao K, Li L, Yi T, Zhao X.
    Arch Gynecol Obstet; 2016 Jan 30; 293(1):163-168. PubMed ID: 26198168
    [Abstract] [Full Text] [Related]

  • 20. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R.
    Cochrane Database Syst Rev; 2022 Sep 26; 9(9):CD015048. PubMed ID: 36161421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.